New triple therapy shows promise for aggressive lung cancer
NCT ID NCT04660097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth or shrink tumors. This is not a cure, but aims to control the disease longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC,EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
-
Sixth People's Hospital of Luoyang
Luoyang, Henan, 471000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial
- New PET scan probe could sharpen lung cancer detection